- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Mabpharm Ltd (2181)
Mabpharm Ltd stock price live, this page displays HK 2181 stock exchange data. View the 2181 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Mabpharm Ltd real time stock price chart below.
What Is the Mabpharm Ltd Stock Price Today?
The Mabpharm Ltd stock price today is 0.480.
What Is the Stock Symbol for Mabpharm Ltd?
The stock symbol for Mabpharm Ltd is "2181."
What Stock Exchange Does Mabpharm Ltd Trade On?
Mabpharm Ltd is listed and trades on the Hong Kong stock exchange.
Is Mabpharm Ltd a Good Stock to Buy?
Determining whether Mabpharm Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2181 quote. (ISIN: KYG5780F1046)
What Is the Mabpharm Ltd Stock Price Today?
The Mabpharm Ltd stock price today is 0.480.
What Is the Stock Symbol for Mabpharm Ltd?
The stock symbol for Mabpharm Ltd is "2181."
What Stock Exchange Does Mabpharm Ltd Trade On?
Mabpharm Ltd is listed and trades on the Hong Kong stock exchange.
Is Mabpharm Ltd a Good Stock to Buy?
Determining whether Mabpharm Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2181 quote. (ISIN: KYG5780F1046)
Hong Kong
Currency in HKD
0.480
+0.010(+2.13%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.480
0.480
52 wk Range
0.250
0.680
2181 Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.4800.480
52 wk Range
0.2500.680
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2181 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
No news in this category
Looks like there are no results in this news category
Mabpharm Company Profile
Mabpharm Limited, a biopharmaceutical company, engages in research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in the People’s Republic of China. The company’s products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for indications of rheumatoid arthritis, Crohn’s disease, etc; and CMAB807 for osteoporosis indications. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X for the treatment of tumor bone metastasis; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis. In addition, the company’s products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB018, a biosimilar candidate for mepolizumab, for the treatment of asthma and eosinophilic granulomatous polyangiitis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab. Further, it is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs. The company was incorporated in 2018 and is headquartered in Taizhou, China.
Compare 2181 to Peers and Sector
Metrics to compare | 2181 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2181PeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.9x | −14.1x | −0.5x | |
PEG Ratio | 1.31 | −0.16 | 0.00 | |
Price/Book | 16.0x | 2.7x | 2.6x | |
Price / LTM Sales | 12.2x | 11.3x | 3.0x | |
Upside (Analyst Target) | - | 17.9% | 54.1% | |
Fair Value Upside | Unlock | 9.5% | 9.4% | Unlock |
FAQ
What Is the Mabpharm (2181) Stock Price Today?
The Mabpharm stock price today is 0.48.
What Stock Exchange Does Mabpharm Trade On?
Mabpharm is listed and trades on the Hong Kong stock exchange.
What Is the Stock Symbol for Mabpharm?
The stock symbol for Mabpharm is "2181."
What Is the Mabpharm Market Cap?
As of today, Mabpharm market cap is 1.98B.
What is Mabpharm Earnings Per Share?
The Mabpharm EPS is -0.05.
From a Technical Analysis Perspective, Is 2181 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.